185 related articles for article (PubMed ID: 20863721)
1. Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer.
Jacobs MA; Stearns V; Wolff AC; Macura K; Argani P; Khouri N; Tsangaris T; Barker PB; Davidson NE; Bhujwalla ZM; Bluemke DA; Ouwerkerk R
Acad Radiol; 2010 Dec; 17(12):1477-85. PubMed ID: 20863721
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.
Jacobs MA; Ouwerkerk R; Wolff AC; Gabrielson E; Warzecha H; Jeter S; Bluemke DA; Wahl R; Stearns V
Breast Cancer Res Treat; 2011 Jul; 128(1):119-26. PubMed ID: 21455671
[TBL] [Abstract][Full Text] [Related]
3. Optical mammography using diffuse optical spectroscopy for monitoring tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
Schaafsma BE; van de Giessen M; Charehbili A; Smit VT; Kroep JR; Lelieveldt BP; Liefers GJ; Chan A; Löwik CW; Dijkstra J; van de Velde CJ; Wasser MN; Vahrmeijer AL
Clin Cancer Res; 2015 Feb; 21(3):577-84. PubMed ID: 25473002
[TBL] [Abstract][Full Text] [Related]
4. Tissue Sodium Concentration Quantification at 7.0-T MRI as an Early Marker for Chemotherapy Response in Breast Cancer: A Feasibility Study.
Zaric O; Farr A; Minarikova L; Lachner S; Asseryanis E; Nagel AM; Weber M; Singer CF; Trattnig S
Radiology; 2021 Apr; 299(1):63-72. PubMed ID: 33591888
[TBL] [Abstract][Full Text] [Related]
5. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
[TBL] [Abstract][Full Text] [Related]
6. Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer.
Kwong MS; Chung GG; Horvath LJ; Ward BA; Hsu AD; Carter D; Tavassoli F; Haffty B; Burtness BA
Cancer J; 2006; 12(3):212-21. PubMed ID: 16803680
[TBL] [Abstract][Full Text] [Related]
7. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
8. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
Cheung YC; Chen SC; Su MY; See LC; Hsueh S; Chang HK; Lin YC; Tsai CS
Breast Cancer Res Treat; 2003 Mar; 78(1):51-8. PubMed ID: 12611457
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
[TBL] [Abstract][Full Text] [Related]
10. Total choline quantification measured by 1H MR spectroscopy as early predictor of response after neoadjuvant treatment for locally advanced breast cancer: The impact of immunohistochemical status.
Drisis S; Flamen P; Ignatiadis M; Metens T; Chao SL; Chintinne M; Lemort M
J Magn Reson Imaging; 2018 Oct; 48(4):982-993. PubMed ID: 29659077
[TBL] [Abstract][Full Text] [Related]
11. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results.
Padhani AR; Hayes C; Assersohn L; Powles T; Makris A; Suckling J; Leach MO; Husband JE
Radiology; 2006 May; 239(2):361-74. PubMed ID: 16543585
[TBL] [Abstract][Full Text] [Related]
12. Diffusion-weighted MRI and MR- volumetry--in the evaluation of tumor response after preoperative chemoradiotherapy in patients with locally advanced rectal cancer.
Birlik B; Obuz F; Elibol FD; Celik AO; Sokmen S; Terzi C; Sagol O; Sarioglu S; Gorken I; Oztop I
Magn Reson Imaging; 2015 Feb; 33(2):201-12. PubMed ID: 25460330
[TBL] [Abstract][Full Text] [Related]
13. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
[TBL] [Abstract][Full Text] [Related]
15. Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.
Bufi E; Belli P; Costantini M; Cipriani A; Di Matteo M; Bonatesta A; Franceschini G; Terribile D; Mulé A; Nardone L; Bonomo L
Clin Breast Cancer; 2015 Oct; 15(5):370-80. PubMed ID: 25891905
[TBL] [Abstract][Full Text] [Related]
16. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
[No Abstract] [Full Text] [Related]
17. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
18. MRI in the evaluation of breast cancer patient response to neoadjuvant chemotherapy: predictive factors for breast conservative surgery.
Nadrljanski MM; Miloševic ZC; Plešinac-Karapandžic V; Maksimovic R
Diagn Interv Radiol; 2013; 19(6):463-70. PubMed ID: 24047722
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
[TBL] [Abstract][Full Text] [Related]
20. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
Scheel JR; Kim E; Partridge SC; Lehman CD; Rosen MA; Bernreuter WK; Pisano ED; Marques HS; Morris EA; Weatherall PT; Polin SM; Newstead GM; Esserman LJ; Schnall MD; Hylton NM;
AJR Am J Roentgenol; 2018 Jun; 210(6):1376-1385. PubMed ID: 29708782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
